 Martin McCarter
Concepts (810)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 52 | 2025 | 761 | 7.770 |
Why?
| | Esophageal Neoplasms | 29 | 2025 | 349 | 5.110 |
Why?
| | Skin Neoplasms | 34 | 2024 | 847 | 4.550 |
Why?
| | Adenocarcinoma | 29 | 2025 | 931 | 3.300 |
Why?
| | Esophagectomy | 20 | 2024 | 135 | 3.300 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2025 | 72 | 2.580 |
Why?
| | Sentinel Lymph Node Biopsy | 23 | 2022 | 118 | 2.550 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 40 | 2.100 |
Why?
| | Neoadjuvant Therapy | 15 | 2025 | 463 | 1.640 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 49 | 1.610 |
Why?
| | Rectal Neoplasms | 8 | 2024 | 158 | 1.590 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 389 | 1.560 |
Why?
| | Dendritic Cells | 13 | 2019 | 499 | 1.540 |
Why?
| | Pancreatic Neoplasms | 15 | 2024 | 928 | 1.520 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 1148 | 1.460 |
Why?
| | Stomach Neoplasms | 6 | 2025 | 128 | 1.380 |
Why?
| | Lymphatic Metastasis | 20 | 2023 | 335 | 1.290 |
Why?
| | Neoplasm Staging | 33 | 2025 | 1470 | 1.260 |
Why?
| | Tumor Escape | 4 | 2017 | 49 | 1.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1962 | 1.120 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 121 | 1.080 |
Why?
| | Humans | 218 | 2026 | 145305 | 1.080 |
Why?
| | Sarcoma | 8 | 2026 | 205 | 1.070 |
Why?
| | Colonic Neoplasms | 7 | 2024 | 260 | 1.060 |
Why?
| | HIV-1 | 17 | 2025 | 897 | 1.060 |
Why?
| | Lymph Nodes | 15 | 2023 | 502 | 1.040 |
Why?
| | Middle Aged | 107 | 2026 | 36021 | 1.040 |
Why?
| | Neoplasms | 14 | 2025 | 2887 | 1.020 |
Why?
| | Anus Neoplasms | 3 | 2024 | 32 | 1.020 |
Why?
| | Aged | 89 | 2026 | 26001 | 1.000 |
Why?
| | Peritoneal Neoplasms | 4 | 2024 | 103 | 0.970 |
Why?
| | Postoperative Complications | 21 | 2025 | 2938 | 0.950 |
Why?
| | Hyperglycemia | 3 | 2020 | 376 | 0.950 |
Why?
| | Retrospective Studies | 57 | 2026 | 17149 | 0.950 |
Why?
| | Intestinal Neoplasms | 2 | 2024 | 30 | 0.940 |
Why?
| | Cytoreduction Surgical Procedures | 5 | 2024 | 67 | 0.920 |
Why?
| | HIV Infections | 21 | 2025 | 3158 | 0.900 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1130 | 0.890 |
Why?
| | Prognosis | 30 | 2025 | 4310 | 0.890 |
Why?
| | Colorectal Neoplasms | 8 | 2025 | 849 | 0.870 |
Why?
| | Laparoscopy | 8 | 2024 | 477 | 0.870 |
Why?
| | Intestine, Small | 2 | 2024 | 166 | 0.840 |
Why?
| | Survival Rate | 23 | 2025 | 2100 | 0.830 |
Why?
| | Male | 121 | 2026 | 72628 | 0.820 |
Why?
| | Female | 132 | 2026 | 78605 | 0.810 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 37 | 0.800 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 677 | 0.780 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 135 | 0.750 |
Why?
| | Lymph Node Excision | 8 | 2022 | 174 | 0.730 |
Why?
| | Tretinoin | 3 | 2023 | 124 | 0.730 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 100 | 0.710 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1127 | 0.690 |
Why?
| | T-Lymphocytes | 8 | 2024 | 1984 | 0.690 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 12 | 0.660 |
Why?
| | Gastrointestinal Microbiome | 9 | 2025 | 772 | 0.660 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 72 | 0.650 |
Why?
| | Anastomotic Leak | 4 | 2024 | 44 | 0.630 |
Why?
| | Radiosurgery | 4 | 2020 | 401 | 0.630 |
Why?
| | Adult | 69 | 2026 | 40627 | 0.630 |
Why?
| | Survival Analysis | 16 | 2022 | 1386 | 0.620 |
Why?
| | Splenectomy | 1 | 2020 | 65 | 0.610 |
Why?
| | Chemoradiotherapy | 6 | 2024 | 239 | 0.610 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 50 | 0.590 |
Why?
| | Ipilimumab | 2 | 2019 | 40 | 0.590 |
Why?
| | Piperazines | 5 | 2014 | 381 | 0.580 |
Why?
| | Myeloid Cells | 3 | 2020 | 148 | 0.580 |
Why?
| | Spleen | 6 | 2017 | 508 | 0.580 |
Why?
| | Ischemic Preconditioning | 3 | 2024 | 47 | 0.580 |
Why?
| | Granulocytes | 2 | 2017 | 80 | 0.560 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 142 | 0.560 |
Why?
| | Pyrimidines | 5 | 2014 | 533 | 0.540 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 573 | 0.540 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 87 | 0.540 |
Why?
| | Monocytes | 2 | 2020 | 538 | 0.530 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 28 | 0.530 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2202 | 0.520 |
Why?
| | Aged, 80 and over | 28 | 2024 | 8295 | 0.510 |
Why?
| | Combined Modality Therapy | 15 | 2024 | 1268 | 0.510 |
Why?
| | Pylorus | 1 | 2017 | 17 | 0.500 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.500 |
Why?
| | Time-to-Treatment | 4 | 2025 | 245 | 0.500 |
Why?
| | Mucous Membrane | 5 | 2024 | 128 | 0.490 |
Why?
| | Follow-Up Studies | 20 | 2025 | 5431 | 0.490 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 918 | 0.490 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 127 | 0.470 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 45 | 0.470 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 201 | 0.470 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 58 | 0.470 |
Why?
| | Treatment Outcome | 29 | 2026 | 11731 | 0.470 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 562 | 0.470 |
Why?
| | Leucovorin | 2 | 2019 | 101 | 0.460 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 154 | 0.450 |
Why?
| | Liver Neoplasms | 6 | 2024 | 785 | 0.440 |
Why?
| | Vitamin B Complex | 1 | 2014 | 40 | 0.430 |
Why?
| | Immune Tolerance | 4 | 2016 | 379 | 0.410 |
Why?
| | Salvage Therapy | 2 | 2014 | 162 | 0.410 |
Why?
| | Esophagogastric Junction | 4 | 2024 | 56 | 0.410 |
Why?
| | Lymphocytes | 3 | 2021 | 382 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 189 | 0.400 |
Why?
| | Pancreatectomy | 5 | 2024 | 285 | 0.400 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 109 | 0.400 |
Why?
| | Pelvis | 1 | 2014 | 124 | 0.390 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.390 |
Why?
| | Mohs Surgery | 1 | 2013 | 29 | 0.390 |
Why?
| | Mutation | 9 | 2025 | 4104 | 0.380 |
Why?
| | Up-Regulation | 5 | 2025 | 852 | 0.380 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 131 | 0.380 |
Why?
| | Immunity, Innate | 5 | 2025 | 846 | 0.370 |
Why?
| | B-Lymphocytes | 4 | 2025 | 877 | 0.370 |
Why?
| | Biopsy | 3 | 2023 | 1079 | 0.370 |
Why?
| | Prospective Studies | 22 | 2025 | 8011 | 0.370 |
Why?
| | Abdominal Neoplasms | 3 | 2025 | 47 | 0.370 |
Why?
| | Microbiota | 5 | 2024 | 781 | 0.360 |
Why?
| | Retroperitoneal Neoplasms | 4 | 2026 | 28 | 0.360 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 736 | 0.360 |
Why?
| | Hematologic Diseases | 1 | 2012 | 66 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 643 | 0.360 |
Why?
| | Anastomosis, Surgical | 3 | 2024 | 159 | 0.360 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.350 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1325 | 0.350 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 60 | 0.350 |
Why?
| | Cytokines | 8 | 2021 | 2066 | 0.340 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 319 | 0.340 |
Why?
| | Cell Movement | 6 | 2025 | 965 | 0.340 |
Why?
| | Dasatinib | 2 | 2024 | 57 | 0.340 |
Why?
| | Palliative Care | 1 | 2019 | 1012 | 0.320 |
Why?
| | Granzymes | 2 | 2021 | 49 | 0.320 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 22 | 0.320 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 469 | 0.320 |
Why?
| | Thrombelastography | 2 | 2024 | 178 | 0.310 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 29 | 0.310 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 137 | 0.310 |
Why?
| | Homosexuality, Male | 3 | 2021 | 223 | 0.300 |
Why?
| | Benzamides | 5 | 2014 | 227 | 0.300 |
Why?
| | Young Adult | 20 | 2025 | 14163 | 0.300 |
Why?
| | Databases, Factual | 7 | 2025 | 1488 | 0.300 |
Why?
| | Interferon-gamma | 6 | 2019 | 784 | 0.300 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 15 | 0.290 |
Why?
| | Immunotherapy | 5 | 2024 | 660 | 0.290 |
Why?
| | Butyrates | 2 | 2021 | 67 | 0.280 |
Why?
| | Interleukin-15 | 2 | 2021 | 97 | 0.280 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 501 | 0.280 |
Why?
| | Barrett Esophagus | 3 | 2020 | 165 | 0.280 |
Why?
| | Medical Oncology | 4 | 2022 | 332 | 0.280 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 98 | 0.280 |
Why?
| | Neoplasm Metastasis | 4 | 2025 | 697 | 0.270 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 425 | 0.270 |
Why?
| | Cell Differentiation | 5 | 2016 | 2053 | 0.270 |
Why?
| | Wounds and Injuries | 4 | 2009 | 961 | 0.270 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 272 | 0.270 |
Why?
| | Interleukin-10 | 4 | 2025 | 310 | 0.270 |
Why?
| | Inflammation Mediators | 2 | 2018 | 509 | 0.270 |
Why?
| | Disease-Free Survival | 8 | 2019 | 771 | 0.260 |
Why?
| | Blood Preservation | 2 | 2009 | 354 | 0.260 |
Why?
| | Nomograms | 2 | 2019 | 59 | 0.250 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 979 | 0.250 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 13 | 0.250 |
Why?
| | General Surgery | 2 | 2007 | 208 | 0.250 |
Why?
| | Immunocompromised Host | 1 | 2008 | 201 | 0.250 |
Why?
| | Dysbiosis | 3 | 2021 | 187 | 0.250 |
Why?
| | Colon | 3 | 2021 | 305 | 0.250 |
Why?
| | Cells, Cultured | 9 | 2021 | 4155 | 0.240 |
Why?
| | Mice | 25 | 2025 | 18394 | 0.240 |
Why?
| | Th2 Cells | 2 | 2005 | 171 | 0.240 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 4 | 0.240 |
Why?
| | Lymphangioma | 1 | 2006 | 9 | 0.240 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 202 | 0.240 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 231 | 0.240 |
Why?
| | Time Factors | 12 | 2024 | 7186 | 0.240 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 24 | 0.240 |
Why?
| | Population Surveillance | 2 | 2021 | 485 | 0.240 |
Why?
| | Transplantation Immunology | 1 | 2005 | 29 | 0.230 |
Why?
| | Ecotype | 1 | 2025 | 16 | 0.230 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 377 | 0.230 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 89 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | Mice, Inbred BALB C | 6 | 2024 | 1253 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 40 | 0.230 |
Why?
| | Vena Cava, Inferior | 1 | 2026 | 81 | 0.230 |
Why?
| | Exome | 2 | 2017 | 227 | 0.230 |
Why?
| | Signal Transduction | 10 | 2025 | 5239 | 0.220 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 14 | 0.220 |
Why?
| | Circulating Tumor DNA | 1 | 2025 | 45 | 0.220 |
Why?
| | Mentors | 1 | 2007 | 219 | 0.220 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 114 | 0.220 |
Why?
| | Catheter Ablation | 4 | 2016 | 353 | 0.220 |
Why?
| | Cellular Microenvironment | 1 | 2025 | 94 | 0.220 |
Why?
| | Computational Biology | 3 | 2025 | 683 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 15 | 0.220 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 111 | 0.220 |
Why?
| | Radiation Injuries | 2 | 2021 | 151 | 0.210 |
Why?
| | Tumor Hypoxia | 1 | 2024 | 7 | 0.210 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 35 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 292 | 0.210 |
Why?
| | Metastasectomy | 1 | 2024 | 19 | 0.210 |
Why?
| | Th1 Cells | 2 | 2019 | 139 | 0.210 |
Why?
| | Virus Replication | 5 | 2017 | 529 | 0.210 |
Why?
| | Gastrectomy | 3 | 2025 | 161 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2005 | 193 | 0.210 |
Why?
| | Hepatectomy | 3 | 2024 | 276 | 0.210 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 27 | 0.210 |
Why?
| | Mice, Nude | 2 | 2024 | 688 | 0.200 |
Why?
| | Interferon-alpha | 3 | 2015 | 197 | 0.200 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 241 | 0.200 |
Why?
| | Lymphocyte Count | 5 | 2017 | 164 | 0.200 |
Why?
| | Cohort Studies | 7 | 2025 | 5982 | 0.200 |
Why?
| | Carcinoma | 2 | 2006 | 228 | 0.200 |
Why?
| | Ruminococcus | 2 | 2021 | 8 | 0.200 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1048 | 0.200 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 221 | 0.200 |
Why?
| | Flow Cytometry | 6 | 2017 | 1173 | 0.200 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 4 | 0.200 |
Why?
| | Immunophenotyping | 3 | 2025 | 322 | 0.200 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 43 | 0.200 |
Why?
| | Esophageal Stenosis | 1 | 2024 | 60 | 0.200 |
Why?
| | Cannabinoids | 1 | 2025 | 182 | 0.190 |
Why?
| | Erythrocytes | 1 | 2009 | 757 | 0.190 |
Why?
| | Feces | 4 | 2021 | 514 | 0.190 |
Why?
| | Adolescent | 15 | 2019 | 22507 | 0.190 |
Why?
| | Animals | 28 | 2025 | 38177 | 0.190 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.190 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 233 | 0.190 |
Why?
| | Lysophospholipids | 1 | 2023 | 78 | 0.190 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 80 | 0.190 |
Why?
| | Specialties, Surgical | 1 | 2023 | 82 | 0.190 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 6 | 0.190 |
Why?
| | Intestines | 2 | 2017 | 358 | 0.190 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 479 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 101 | 0.190 |
Why?
| | Cell Count | 2 | 2017 | 321 | 0.180 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 190 | 0.180 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 560 | 0.180 |
Why?
| | Cryosurgery | 2 | 2019 | 47 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.180 |
Why?
| | Ampulla of Vater | 2 | 2024 | 39 | 0.180 |
Why?
| | HIV Seropositivity | 1 | 2022 | 119 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.180 |
Why?
| | Preoperative Care | 3 | 2018 | 382 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.180 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 77 | 0.180 |
Why?
| | Patient Selection | 3 | 2014 | 726 | 0.170 |
Why?
| | Bacteria | 3 | 2018 | 891 | 0.170 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3560 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 163 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2745 | 0.170 |
Why?
| | Esophagoscopy | 2 | 2020 | 221 | 0.170 |
Why?
| | Acinetobacter | 1 | 2021 | 16 | 0.170 |
Why?
| | Germinal Center | 2 | 2025 | 67 | 0.170 |
Why?
| | Critical Pathways | 1 | 2022 | 108 | 0.170 |
Why?
| | Carcinoma in Situ | 1 | 2001 | 44 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 177 | 0.170 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Disease Progression | 2 | 2022 | 2855 | 0.170 |
Why?
| | Glucose | 3 | 2020 | 1049 | 0.170 |
Why?
| | Gamma Rays | 1 | 2021 | 56 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 308 | 0.160 |
Why?
| | Interleukin-2 | 5 | 2022 | 437 | 0.160 |
Why?
| | Carcinoma, Lobular | 1 | 2001 | 56 | 0.160 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2001 | 88 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 687 | 0.160 |
Why?
| | Risk Factors | 12 | 2024 | 10816 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 77 | 0.160 |
Why?
| | Delivery of Health Care | 2 | 2021 | 947 | 0.160 |
Why?
| | Diarrhea | 3 | 2008 | 194 | 0.160 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 10 | 0.160 |
Why?
| | Bacterial Translocation | 2 | 2019 | 52 | 0.160 |
Why?
| | Transcriptome | 2 | 2025 | 1046 | 0.160 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.160 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 39 | 0.160 |
Why?
| | Interleukins | 2 | 2019 | 248 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 974 | 0.160 |
Why?
| | Platelet Count | 1 | 2020 | 96 | 0.150 |
Why?
| | Software | 1 | 2025 | 692 | 0.150 |
Why?
| | Guidelines as Topic | 2 | 2018 | 268 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 77 | 0.150 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.150 |
Why?
| | Apoptosis | 5 | 2021 | 2430 | 0.150 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 83 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1135 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 220 | 0.150 |
Why?
| | Cell Proliferation | 6 | 2021 | 2506 | 0.150 |
Why?
| | United States | 14 | 2025 | 16051 | 0.150 |
Why?
| | Dacarbazine | 4 | 2012 | 100 | 0.150 |
Why?
| | Scalp | 1 | 2019 | 37 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 10 | 0.150 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 6 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2020 | 316 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2019 | 19 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2021 | 126 | 0.150 |
Why?
| | Palatine Tonsil | 4 | 2025 | 55 | 0.150 |
Why?
| | CD4 Antigens | 2 | 2011 | 139 | 0.150 |
Why?
| | Haploinsufficiency | 1 | 2019 | 55 | 0.150 |
Why?
| | Mastocytosis | 1 | 2019 | 11 | 0.150 |
Why?
| | Stomach | 3 | 2024 | 109 | 0.150 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 17 | 0.150 |
Why?
| | Patient Care Planning | 2 | 2016 | 171 | 0.150 |
Why?
| | Surgeons | 1 | 2023 | 340 | 0.140 |
Why?
| | Nutritional Support | 1 | 2019 | 39 | 0.140 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 54 | 0.140 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 220 | 0.140 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 47 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 220 | 0.140 |
Why?
| | Intestinal Perforation | 1 | 2019 | 44 | 0.140 |
Why?
| | Photochemotherapy | 1 | 2019 | 39 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 354 | 0.140 |
Why?
| | Decision Making | 2 | 2019 | 980 | 0.140 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 9 | 0.140 |
Why?
| | Skin Pigmentation | 1 | 2019 | 48 | 0.140 |
Why?
| | Th17 Cells | 1 | 2019 | 101 | 0.140 |
Why?
| | Dilatation | 1 | 2019 | 72 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 104 | 0.140 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 81 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1462 | 0.140 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 56 | 0.140 |
Why?
| | Survivors | 2 | 2015 | 520 | 0.140 |
Why?
| | Esophagus | 1 | 2020 | 261 | 0.140 |
Why?
| | Breast Neoplasms | 2 | 2001 | 2464 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 550 | 0.140 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 348 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Brachytherapy | 1 | 2019 | 134 | 0.130 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.130 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 176 | 0.130 |
Why?
| | Hospitals | 2 | 2021 | 733 | 0.130 |
Why?
| | Down-Regulation | 1 | 2020 | 627 | 0.130 |
Why?
| | HIV | 1 | 2019 | 250 | 0.130 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 21 | 0.130 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 38 | 0.130 |
Why?
| | Risk Assessment | 4 | 2024 | 3686 | 0.130 |
Why?
| | Viral Tropism | 1 | 2017 | 36 | 0.130 |
Why?
| | Food, Formulated | 1 | 1997 | 16 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Deglutition Disorders | 1 | 2019 | 147 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 27 | 0.130 |
Why?
| | Laser Therapy | 1 | 2019 | 135 | 0.130 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 324 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 93 | 0.130 |
Why?
| | Liver | 4 | 2016 | 1893 | 0.130 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 142 | 0.130 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2025 | 113 | 0.130 |
Why?
| | Gastric Emptying | 1 | 2017 | 36 | 0.130 |
Why?
| | Enteral Nutrition | 2 | 2010 | 216 | 0.120 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 65 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 647 | 0.120 |
Why?
| | Arginine | 1 | 1998 | 262 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 237 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1145 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 991 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 211 | 0.120 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 50 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 826 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 226 | 0.120 |
Why?
| | Nutritional Status | 1 | 2019 | 354 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 48 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.120 |
Why?
| | Immunologic Memory | 2 | 2016 | 366 | 0.120 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.120 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 67 | 0.120 |
Why?
| | Bystander Effect | 1 | 2016 | 19 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 110 | 0.120 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 132 | 0.120 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2118 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 99 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 28 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 415 | 0.120 |
Why?
| | Mortality | 1 | 2018 | 376 | 0.120 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 104 | 0.110 |
Why?
| | Morbidity | 3 | 2023 | 324 | 0.110 |
Why?
| | Exons | 3 | 2019 | 361 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 851 | 0.110 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 56 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 11 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 241 | 0.110 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 12 | 0.110 |
Why?
| | Perioperative Care | 1 | 2018 | 232 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1217 | 0.110 |
Why?
| | Adenoma | 1 | 2017 | 218 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1747 | 0.110 |
Why?
| | Postoperative Care | 1 | 1997 | 290 | 0.110 |
Why?
| | Ileus | 1 | 2014 | 13 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 550 | 0.110 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 7 | 0.110 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 92 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 346 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4284 | 0.110 |
Why?
| | Vinblastine | 2 | 2012 | 75 | 0.110 |
Why?
| | Endosonography | 1 | 2016 | 158 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 931 | 0.100 |
Why?
| | Viral Load | 5 | 2018 | 527 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2021 | 1169 | 0.100 |
Why?
| | Ethanol | 1 | 2019 | 627 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 920 | 0.100 |
Why?
| | Quality of Life | 3 | 2019 | 3197 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 66 | 0.100 |
Why?
| | Dietary Supplements | 1 | 1998 | 576 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 54 | 0.100 |
Why?
| | Fluorouracil | 2 | 2019 | 235 | 0.100 |
Why?
| | Tumor Burden | 4 | 2022 | 323 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2652 | 0.100 |
Why?
| | Colectomy | 3 | 2008 | 107 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 208 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 886 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 87 | 0.100 |
Why?
| | RNA, Viral | 3 | 2013 | 688 | 0.100 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 70 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 373 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 475 | 0.090 |
Why?
| | Oligopeptides | 1 | 2014 | 269 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1894 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2015 | 1992 | 0.090 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.090 |
Why?
| | HIV Antibodies | 1 | 2013 | 61 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2371 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 529 | 0.090 |
Why?
| | Ablation Techniques | 1 | 2012 | 36 | 0.090 |
Why?
| | Cisplatin | 2 | 2012 | 336 | 0.090 |
Why?
| | Mice, Knockout | 4 | 2024 | 3127 | 0.090 |
Why?
| | Biological Therapy | 1 | 2012 | 28 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 99 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2398 | 0.090 |
Why?
| | Hospital Mortality | 2 | 2016 | 1035 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 140 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 192 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 43 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 129 | 0.090 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 201 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 559 | 0.090 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.090 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 23 | 0.080 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1787 | 0.080 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 194 | 0.080 |
Why?
| | Macrophages | 2 | 2001 | 1514 | 0.080 |
Why?
| | Ligands | 2 | 2023 | 676 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1540 | 0.080 |
Why?
| | Cell Separation | 2 | 2010 | 307 | 0.080 |
Why?
| | Extremities | 2 | 2022 | 140 | 0.080 |
Why?
| | Endocytosis | 1 | 2011 | 168 | 0.080 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 8 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 183 | 0.080 |
Why?
| | Interleukin-23 | 1 | 2010 | 16 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 692 | 0.080 |
Why?
| | Heparin | 1 | 2012 | 244 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 339 | 0.080 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 43 | 0.080 |
Why?
| | Gastric Fistula | 1 | 2010 | 9 | 0.080 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 14 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 342 | 0.080 |
Why?
| | Antigens, CD | 2 | 2015 | 555 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 238 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 340 | 0.080 |
Why?
| | Antiviral Agents | 1 | 2015 | 768 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 158 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1500 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 853 | 0.070 |
Why?
| | Rosaniline Dyes | 3 | 2007 | 15 | 0.070 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 148 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 6007 | 0.070 |
Why?
| | Cell Transplantation | 1 | 2009 | 39 | 0.070 |
Why?
| | Odds Ratio | 3 | 2019 | 1077 | 0.070 |
Why?
| | Double-Blind Method | 4 | 2014 | 2033 | 0.070 |
Why?
| | Immunoglobulins | 2 | 2023 | 160 | 0.070 |
Why?
| | Escherichia coli | 1 | 2014 | 855 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 842 | 0.070 |
Why?
| | Paracrine Communication | 1 | 2009 | 67 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 668 | 0.070 |
Why?
| | Phenotype | 5 | 2019 | 3172 | 0.070 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 74 | 0.070 |
Why?
| | Hyalin | 1 | 2008 | 3 | 0.070 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 29 | 0.070 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 7 | 0.070 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 153 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 412 | 0.070 |
Why?
| | ROC Curve | 2 | 2024 | 615 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1183 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 3339 | 0.070 |
Why?
| | Gastrostomy | 1 | 2010 | 130 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2007 | 206 | 0.070 |
Why?
| | ras Proteins | 1 | 2009 | 151 | 0.070 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 409 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 89 | 0.070 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 82 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 967 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 264 | 0.070 |
Why?
| | Logistic Models | 4 | 2016 | 2119 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3613 | 0.060 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 80 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2019 | 395 | 0.060 |
Why?
| | Career Mobility | 1 | 2007 | 72 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2008 | 221 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 598 | 0.060 |
Why?
| | Interleukin-6 | 4 | 1999 | 782 | 0.060 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.060 |
Why?
| | Length of Stay | 3 | 2019 | 1342 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2019 | 342 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1718 | 0.060 |
Why?
| | Anticoagulants | 1 | 2012 | 726 | 0.060 |
Why?
| | New York | 2 | 2023 | 127 | 0.060 |
Why?
| | Laparotomy | 1 | 2007 | 112 | 0.060 |
Why?
| | Phylogeny | 2 | 2024 | 1020 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.060 |
Why?
| | Watchful Waiting | 2 | 2018 | 90 | 0.060 |
Why?
| | History, 20th Century | 1 | 2007 | 327 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2025 | 14 | 0.060 |
Why?
| | Vascular Patency | 1 | 2026 | 121 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2009 | 405 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 51 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1698 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 118 | 0.060 |
Why?
| | Critical Care | 1 | 2012 | 698 | 0.060 |
Why?
| | Collagen | 1 | 2008 | 456 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 624 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 863 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 444 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 766 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 273 | 0.060 |
Why?
| | Quality Control | 1 | 2025 | 163 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 60 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 161 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 39 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 397 | 0.050 |
Why?
| | Chromones | 1 | 2024 | 42 | 0.050 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 29 | 0.050 |
Why?
| | Nitric Oxide | 2 | 2001 | 897 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2008 | 288 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2007 | 303 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 39 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2005 | 2833 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 129 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 551 | 0.050 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 271 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 107 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 64 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1296 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2026 | 234 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 357 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 24 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 276 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 510 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 40 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 248 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 410 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 356 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 17 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 176 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 60 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 44 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 110 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 51 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 980 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 311 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 16 | 0.040 |
Why?
| | Technetium | 1 | 2001 | 10 | 0.040 |
Why?
| | Corticosterone | 1 | 2003 | 244 | 0.040 |
Why?
| | Injections, Intradermal | 1 | 2001 | 11 | 0.040 |
Why?
| | Child | 4 | 2019 | 22712 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2007 | 477 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2003 | 136 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 81 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2026 | 413 | 0.040 |
Why?
| | NF-kappa B | 1 | 2005 | 662 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 257 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 331 | 0.040 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2001 | 6 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 113 | 0.040 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 40 | 0.040 |
Why?
| | Leptin | 1 | 2003 | 247 | 0.040 |
Why?
| | Mediastinoscopy | 1 | 2021 | 5 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 434 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 80 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2001 | 183 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 252 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Glycoproteins | 2 | 2015 | 355 | 0.040 |
Why?
| | Cholangiography | 1 | 2000 | 10 | 0.040 |
Why?
| | Workload | 1 | 2002 | 170 | 0.040 |
Why?
| | Precision Medicine | 2 | 2016 | 460 | 0.040 |
Why?
| | Veterans | 1 | 2013 | 1615 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 256 | 0.040 |
Why?
| | Probability | 1 | 2001 | 312 | 0.040 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 343 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1327 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 62 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 469 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 17 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 686 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 207 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 427 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 1003 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 93 | 0.040 |
Why?
| | Quality of Health Care | 3 | 2012 | 696 | 0.040 |
Why?
| | Body Mass Index | 1 | 2008 | 2439 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 41 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1036 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 157 | 0.040 |
Why?
| | Eating | 2 | 2003 | 392 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 256 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 51 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 846 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1311 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 586 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 81 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 463 | 0.040 |
Why?
| | Montana | 1 | 2018 | 19 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 28 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 339 | 0.030 |
Why?
| | Mitogens | 1 | 1998 | 55 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2019 | 235 | 0.030 |
Why?
| | Keratins | 2 | 2010 | 172 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 706 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 122 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 737 | 0.030 |
Why?
| | Cachexia | 1 | 1999 | 75 | 0.030 |
Why?
| | Pedigree | 1 | 2019 | 514 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 533 | 0.030 |
Why?
| | Jejunostomy | 1 | 1997 | 14 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 198 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 71 | 0.030 |
Why?
| | Dinoprostone | 1 | 1998 | 178 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 160 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 12 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1503 | 0.030 |
Why?
| | Candidiasis | 1 | 1997 | 64 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 17 | 0.030 |
Why?
| | Femoral Fractures | 1 | 1998 | 82 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 37 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 94 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 176 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 183 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 630 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 173 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 289 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 251 | 0.030 |
Why?
| | Neck | 1 | 2017 | 108 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 220 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 6 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 27 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 336 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 431 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 223 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 34 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 983 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 80 | 0.030 |
Why?
| | Histones | 1 | 2021 | 673 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 174 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 521 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2283 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 103 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 26 | 0.030 |
Why?
| | Virion | 1 | 2015 | 111 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 193 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 464 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 141 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 744 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 492 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1681 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 433 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5883 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 1103 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 90 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 600 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 535 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 25 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 111 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 1001 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 131 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 824 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 760 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 280 | 0.020 |
Why?
| | Phosphorylation | 1 | 1998 | 1735 | 0.020 |
Why?
| | Caspase 1 | 1 | 2014 | 148 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 278 | 0.020 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.020 |
Why?
| | Autoantigens | 1 | 2016 | 429 | 0.020 |
Why?
| | Cell Lineage | 1 | 2015 | 378 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3888 | 0.020 |
Why?
| | Inflammation | 2 | 2019 | 2881 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 360 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 55 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3419 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 29 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 85 | 0.020 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 60 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2013 | 181 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1568 | 0.020 |
Why?
| | International Agencies | 1 | 2012 | 30 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 53 | 0.020 |
Why?
| | Hemorrhage | 1 | 1998 | 810 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 198 | 0.020 |
Why?
| | Thoracotomy | 1 | 2012 | 83 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 89 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 396 | 0.020 |
Why?
| | Homeostasis | 1 | 2016 | 641 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 310 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 66 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1185 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 299 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 70 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 369 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1261 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 205 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 574 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 783 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 167 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 306 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1247 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 271 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 392 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1490 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 319 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 324 | 0.020 |
Why?
| | Risk | 1 | 2013 | 912 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 610 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 34 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1099 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1328 | 0.020 |
Why?
| | Universities | 1 | 2013 | 453 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 635 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 187 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 151 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2892 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1814 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 64 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 12 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 53 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 465 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2158 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 140 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 141 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 143 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 25 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 178 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 893 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 42 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 57 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2931 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 88 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 949 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 76 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 253 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 105 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1619 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2115 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 266 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2192 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 308 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 1031 | 0.020 |
Why?
| | Swine | 1 | 2010 | 835 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 512 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 708 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 5 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 223 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 242 | 0.010 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 175 | 0.010 |
Why?
| | Whole Body Imaging | 1 | 2006 | 29 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1054 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2609 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4580 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 330 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 418 | 0.010 |
Why?
| | Radiotherapy | 1 | 2006 | 206 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10101 | 0.010 |
Why?
| | Patient Discharge | 1 | 2011 | 987 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2191 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 115 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 58 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 71 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 32 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 83 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4579 | 0.010 |
Why?
| | Work Schedule Tolerance | 1 | 2002 | 51 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 363 | 0.010 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 99 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 46 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 27 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 45 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 251 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 246 | 0.010 |
Why?
| | Continuity of Patient Care | 1 | 2002 | 293 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 64 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 34 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 187 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 61 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2032 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3085 | 0.010 |
Why?
| | RNA | 1 | 2001 | 940 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 605 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1196 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 7208 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1499 | 0.000 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|